The generic drug maker said that under the settlement, it would have the right to sell doxepin hydrochloride tablets in the 3-mg and 6-mg strengths starting in January 2020. The drug is a generic version of Somaxon’s Silenor.

Mylan will have the right to sell its generic version of Silenor for 180 days under a license from Somaxon, a period that may be extended for up to 360 days, after which Mylan can sell its version of the drug under its own regulatory approval application.